Patient‐reported ability to have intercourse · men with Peyronie's disease (stable phase)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · men with Peyronie's disease (stable phase)
1 finding from 1 review
Treatment‐related adverse effects · men with Peyronie's disease (stable phase)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Degree of penile curvature · men with Peyronie's disease (stable phase)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment discontinuation · men with Peyronie's disease (stable phase)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Degree of penile curvature · men with acute (maximum of 12 months) Peyronie's disease with no prior treatment and no evidence of calcified plaques (pain during…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment discontinuation · men with acute (maximum of 12 months) Peyronie's disease with no prior treatment and no evidence of calcified plaques (pain during…
It is very uncertain whether potassium paraaminobenzoate changes discontinuation from treatment compared with placebo (very low certainty).
1 finding from 1 review
Reduction or prevention of kidney disease progression · people with sickle cell disease
1 finding from 1 review
Serious adverse events · people with sickle cell disease
Hydroxyurea showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Quality of life · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Reduction or prevention of kidney disease progression · people with sickle cell disease
1 finding from 1 review
Serious adverse events · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (12 months) · weight reduction in obesity to improve survival in women with endometrial cancer
1 finding from 1 review
Overall survival (24 months) · weight reduction in obesity to improve survival in women with endometrial cancer
It is very uncertain whether summary of findings table ‐ Lifestyle intervention changes overall survival (24 months) compared with usual care compared to placebo (very low certainty).
1 finding from 1 review
Adverse events – musculoskeletal · weight reduction in obesity to improve survival in women with endometrial cancer
It is very uncertain whether summary of findings table ‐ Lifestyle intervention changes adverse events – musculoskeletal compared with usual care compared to placebo (very low certainty).
1 finding from 1 review
Cancer‐specific survival (24 months) (Number of cancer‐related deaths) · weight reduction in obesity to improve survival in women with endometrial cancer
1 finding from 1 review
Weight loss (change in kg weight) · weight reduction in obesity to improve survival in women with endometrial cancer
1 finding from 1 review
Cardiovascular and metabolic event frequency (12 months) (Number of strokes, myocardial infarctions and hospitalisations for heart failure) · weight reduction in obesity to improve survival in women with endometrial cancer
Summary of findings table ‐ Lifestyle intervention showed no clear difference in cardiovascular and metabolic event frequency (6 months) compared with usual care compared to placebo (low certainty).
1 finding from 1 review